Blood cancers, Myelofibrosis, Polycythaemia, Thrombocythaemia
Results
Phase 1
This trial looked at ruxolitinib for people who had myelofibrosis and a low number of .
Myelofibrosis is a rare blood disorder. It is a condition that causes scarring of the bone marrow. A small number of people with myelofibrosis go on to develop .
People could join the trial between 2011 and 2019. The team published the final results in 2022.
Recruitment start: 20 June 2011
Recruitment end: 1 December 2019
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Claire Harrison
Experimental Cancer Medicine Centre (ECMC)
Novartis
Last reviewed: 19 Mar 2026
CRUK internal database number: 8374
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
Search our clinical trials database for all cancer trials and studies recruiting in the UK.
Connect with other people affected by cancer and share your experiences.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
